Protalix presents corporate overview highlighting Elfabrio commercialization strategy
Protalix BioTherapeutics released a corporate presentation dated May 2026 outlining its rare disease treatment pipeline and Elfabrio commercialization plans. The filing includes forward-looking statements regarding cash runway and product commercialization, with risks related to
View filing at SEC.gov →